Literature DB >> 16875905

Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department.

Frank Peacock1, Deborah L Morris, Saif Anwaruddin, Robert H Christenson, Paul O Collinson, Steve W Goodacre, James L Januzzi, Robert L Jesse, Juan C Kaski, Michael C Kontos, Guillaume Lefevre, Dave Mutrie, Manas K Sinha, Denise Uettwiller-Geiger, Charles V Pollack.   

Abstract

BACKGROUND: Because of possible adverse outcomes, many of the >6 million annual emergency department (ED) patients with suspected acute coronary syndromes (ACS) undergo extensive evaluations. To minimize medical errors, chest pain evaluations are structured to identify accurately nearly 100% of patients with ACS. This is at a cost of negative evaluation rates that can exceed 90%. Ischemia-modified albumin (IMA), a serum biomarker with a high negative predictive value (NPV) at ED presentation, may exclude ACS. Our objective was to perform a meta-analysis of IMA use for ACS risk stratification.
METHODS: By computer literature search and communication with authors of unpublished information, all IMA data were considered. This analysis included studies if they reported IMA results from an ED presentation for suspected ACS. We defined a negative triple prediction test (TPT) as a nondiagnostic electrocardiogram, negative troponin, and negative IMA.
RESULTS: Eight studies of >1800 patients met the entry criteria. The TPT sensitivity and NPV for acute ACS were 94.4% and 97.1% and, for longer-term outcomes, were 89.2% and 94.5%, respectively.
CONCLUSIONS: A negative TPT of a nondiagnostic electrocardiogram, negative troponin, and negative IMA has a high NPV for excluding ACS in the ED.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875905     DOI: 10.1016/j.ahj.2005.12.024

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  25 in total

1.  Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes.

Authors:  C Bhakthavatsala Reddy; Cijo Cyriac; Hrishikesh B Desle
Journal:  Indian Heart J       Date:  2014-12-22

2.  Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?

Authors:  Aysel Kiyici; Idris Mehmetoğlu; Hatice Karaoğlan; Hüseyin Atalay; Yalçin Solak; Süleyman Türk
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.

Authors:  Amira Abdel Moneam Adly; Nayera Hazaa Khalil ElSherif; Eman Abdel Rahman Ismail; Yosra Abdelzaher Ibrahim; Gamal Niazi; Sara Hamed Elmetwally
Journal:  Redox Rep       Date:  2017-03-13       Impact factor: 4.412

Review 4.  Novel Risk Stratification Assays for Acute Coronary Syndrome.

Authors:  Haitham M Ahmed; Stanley L Hazen
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  The usefulness of albumin-adjusted ischemia-modified albumin index as early detecting marker for ischemic stroke.

Authors:  Jung Hwan Ahn; Sang Cheon Choi; Wee Gyo Lee; Yoon Seok Jung
Journal:  Neurol Sci       Date:  2010-12-11       Impact factor: 3.307

6.  Serum and saliva levels of ischemia-modified albumin in patients with acute myocardial infarction.

Authors:  Aysun Toker; Alpay Aribas; F Hümeyra Yerlikaya; Erkan Tasyurek; Kürşat Akbuğa
Journal:  J Clin Lab Anal       Date:  2013-02-11       Impact factor: 2.352

7.  Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain.

Authors:  A F Manini; J Ilgen; V E Noble; F Bamberg; W Koenig; J S Bohan; U Hoffmann
Journal:  Emerg Med J       Date:  2009-11       Impact factor: 2.740

8.  Ischemia-modified albumin measured with ultra-filtration assay in early diagnosis of acute coronary syndrome.

Authors:  Shu-Ming Pan; Chao-Yang Tong; Qing Lin; Chen-Ling Yao; Jie Zhao; Zhi Deng
Journal:  World J Emerg Med       Date:  2010

Review 9.  Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome.

Authors:  J C Deddens; J M Colijn; M I F J Oerlemans; G Pasterkamp; S A Chamuleau; P A Doevendans; J P G Sluijter
Journal:  J Cardiovasc Transl Res       Date:  2013-07-30       Impact factor: 4.132

10.  The clinical assessment of ischaemia modified albumin and troponin I in the early diagnosis of the acute coronary syndrome.

Authors:  Sangita M Patil; M P Banker; Ramchandra K Padalkar; Abhijit P Pathak; Sonali S Bhagat; Rahul A Ghone; Anjali S Phatake
Journal:  J Clin Diagn Res       Date:  2013-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.